222 related articles for article (PubMed ID: 26421813)
1. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma--a systematic review.
Clement SC; Peeters RP; Ronckers CM; Links TP; van den Heuvel-Eibrink MM; Nieveen van Dijkum EJ; van Rijn RR; van der Pal HJ; Neggers SJ; Kremer LC; van Eck-Smit BL; van Santen HM
Cancer Treat Rev; 2015 Dec; 41(10):925-34. PubMed ID: 26421813
[TBL] [Abstract][Full Text] [Related]
2. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin.
Rosario PW; Calsolari MR
Thyroid; 2013 May; 23(5):617-9. PubMed ID: 23136908
[TBL] [Abstract][Full Text] [Related]
3. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
4. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.
Ko KY; Kao CH; Lin CL; Huang WS; Yen RF
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1172-8. PubMed ID: 25900274
[TBL] [Abstract][Full Text] [Related]
5. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors.
Sawka AM; Lakra DC; Lea J; Alshehri B; Tsang RW; Brierley JD; Straus S; Thabane L; Gafni A; Ezzat S; George SR; Goldstein DP
Clin Endocrinol (Oxf); 2008 Sep; 69(3):479-90. PubMed ID: 18284643
[TBL] [Abstract][Full Text] [Related]
6. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
7. Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up.
Baudin C; Bressand A; Buffet C; Menegaux F; Soret M; Lê AT; Cardon T; Broggio D; Bassinet C; Huet C; Armengol G; Richardson DB; Leenhardt L; Bernier MO; Lussey-Lepoutre C
Thyroid; 2023 Sep; 33(9):1100-1109. PubMed ID: 37300484
[No Abstract] [Full Text] [Related]
8. Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.
Auttara-Atthakorn A; Sungmala J; Anothaisintawee T; Reutrakul S; Sriphrapradang C
Front Endocrinol (Lausanne); 2022; 13():960265. PubMed ID: 36105397
[TBL] [Abstract][Full Text] [Related]
9. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.
Solans R; Bosch JA; Galofré P; Porta F; Roselló J; Selva-O'Callagan A; Vilardell M
J Nucl Med; 2001 May; 42(5):738-43. PubMed ID: 11337569
[TBL] [Abstract][Full Text] [Related]
10. Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer.
Albano D; Bertagna F; Panarotto MB; Giubbini R
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436606
[TBL] [Abstract][Full Text] [Related]
11. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
Bhattacharyya N; Chien W
Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
[TBL] [Abstract][Full Text] [Related]
12. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
[TBL] [Abstract][Full Text] [Related]
14. Effects of Radioiodine Treatment on Salivary Gland Function in Patients with Differentiated Thyroid Carcinoma: A Prospective Study.
Klein Hesselink EN; Brouwers AH; de Jong JR; van der Horst-Schrivers AN; Coppes RP; Lefrandt JD; Jager PL; Vissink A; Links TP
J Nucl Med; 2016 Nov; 57(11):1685-1691. PubMed ID: 27339871
[TBL] [Abstract][Full Text] [Related]
15. Dual malignancies in the setting of differentiated thyroid carcinoma: their synchronous or metachronous nature, impact of radioiodine treatment on occurrence of second malignancy and other associated variables.
Gandhi S; Abhyankar A; Basu S
Nucl Med Commun; 2014 Feb; 35(2):205-9. PubMed ID: 24217429
[TBL] [Abstract][Full Text] [Related]
16. Radioactive iodine: An unappreciated threat to salivary gland function.
Sunavala-Dossabhoy G
Oral Dis; 2018 Mar; 24(1-2):198-201. PubMed ID: 29480611
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.
Reiners C; Schneider R; Platonova T; Fridman M; Malzahn U; Mäder U; Vrachimis A; Bogdanova T; Krajewska J; Elisei R; Vaisman F; Mihailovic J; Costa G; Drozd V
Front Endocrinol (Lausanne); 2020; 11():381. PubMed ID: 32754115
[TBL] [Abstract][Full Text] [Related]
18. Salivary gland malignancy and radioiodine therapy for thyroid cancer.
Klubo-Gwiezdzinska J; Van Nostrand D; Burman KD; Vasko V; Chia S; Deng T; Kulkarni K; Wartofsky L
Thyroid; 2010 Jun; 20(6):647-51. PubMed ID: 20470209
[TBL] [Abstract][Full Text] [Related]
19. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment.
Fallahi B; Adabi K; Majidi M; Fard-Esfahani A; Heshmat R; Larijani B; Haghpanah V
Clin Nucl Med; 2011 Apr; 36(4):277-82. PubMed ID: 21368600
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
Maghsoomi Z; Emami Z; Malboosbaf R; Malek M; Khamseh ME
BMC Cancer; 2021 May; 21(1):579. PubMed ID: 34016077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]